| Ytd | -25.33% | |
| 1y | 31.35% |
| Open | 3.96 | Prev Close | 3.97 | Low | 3.93 | High | 4.01 | Mkt Cap | 223.69M |
| Vol | 266.66K | Avg Vol | 650.82K | EPS | -1.34 | P/E | -2.97 | Forward P/E | -1.61 |
| Beta | 1.79 | Short Ratio | 14.46 | Inst. Own | 51.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.03 | 200-d Avg | 5.22 | 1yr Est | 26.40 |
TARA News
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.36) per share which missed the a
Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the cur
Shares of Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) have received an average ratin
Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, whic
MIAMI, July 20, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL) today announced the appointme
NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-sta
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002
Protara Therapeutics Inc. (NASDAQ:TARA) reported updated 12-month Phase 2 data for TARA-002 in patie
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-mo
The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malfor
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-s
Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) was the recipient of a large increase in
Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002
Protara Therapeutics (NASDAQ: TARA) executives outlined progress across the company's two clinical-s
Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Inva
Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse event
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-st
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-st
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
Friday's session saw 225 companies set new 52-week lows.
On Wednesday, 179 companies reached new 52-week lows.
Tuesday's session saw 184 companies set new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
Wednesday's session saw 784 companies set new 52-week lows.